Nab-Paclitaxel/Bevacizumab Combo Shows Potential In Triple-Negative Breast Cancer
 

WASHINGTON D.C. - New findings identify a possible role for nab-paclitaxel (AbraxaneR for Injectable Suspension) in tandem with bevacizumab for the treatment of triple-negative breast cancer, a notoriously clinically challenging subtype of breast cancer...

More...